VALINE

US Previously Marketed

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C5H11NO2
Molecular Weight	117.1463
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)[C@H](N)C(O)=O

InChI

InChIKey=KZSNJWFQEVHDMF-BYPYZUCNSA-N

InChI=1S/C5H11NO2/c1-3(2)4(6)5(7)8/h3-4H,6H2,1-2H3,(H,7,8)/t4-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C5H11NO2
Molecular Weight	117.1463
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.drugbank.ca/drugs/DB00161
Curator's Comment: description was created based on several sources, including http://medical-dictionary.thefreedictionary.com/valine

Valine is an α-amino acid that is used in the biosynthesis of proteins. It is essential in humans, meaning the body cannot synthesize it and thus it must be obtained from the diet. There is a mixed scientivic evidence that as a dietary supplement valine improves training efficacy, delays central fatigue.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
tryptophan transport 1 Target ID: GO:0015827 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16424144	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Burns 17 Sources: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016822	Primary		Approved 8583	FREAMINE III 10% Approved Use Parenteral nutrition with 8.5% FreAmine® III (Amino Acid Injection) with Electrolytes is indicated to prevent nitrogen loss or treat negative nitrogen balance in adults and pediatric patients, where (1) the alimentary tract, by the oral, gastrostomy, or jejunostomy route, cannot or should not be used, or adequate protein intake is not feasible by these routes; (2) gastrointestinal absorption of protein is impaired; or (3) protein requirements are substantially increased as with extensive burns. Dosage, route of administration, and concomitant infusion of non-protein calories are dependent on various factors, such as nutritional metabolic status of the patient, anticipated duration of parenteral nutritional support, and vein tolerance Launch Date 1971
Central fatigue 1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26785372	Preventing		Natural Metabolite	Unknown Approved Use There is a mixed scientivic evidence that as a dietary supplement valine improves training efficacy, delays central fatigue.

C_max

Value	Dose	Co-administered	Analyte	Population
12.36 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26119505/	60 mg/kg single, oral dose: 60 mg/kg route of administration: Oral experiment type: SINGLE co-administered:		VALINE plasma	Canis lupus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
40.3 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26119505/	60 mg/kg single, oral dose: 60 mg/kg route of administration: Oral experiment type: SINGLE co-administered:		VALINE plasma	Canis lupus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.42 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26119505/	60 mg/kg single, oral dose: 60 mg/kg route of administration: Oral experiment type: SINGLE co-administered:		VALINE plasma	Canis lupus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:27266	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:27266
ChemicalBook	CB5312867	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5312867
eMolecules	514157	https://www.emolecules.com/cgi-bin/more?vid=514157
MolPort	MolPort-039-060-192	https://www.molport.com/shop/molecule-link/MolPort-039-060-192

PubMed

Title	Date	PubMed
Reduction of large neutral amino acid levels in plasma and brain of hyperleucinemic rats.	2001-05	11248401
Multiple transport pathways for dibasic amino acids in the larval midgut of the silkworm Bombyx mori.	2001-04-27	11267901
Effects of pituitary adenylate cyclase activating polypeptide on lumbosacral preganglionic neurons in the neonatal rat spinal cord.	2001-03-23	11259781
Codon 89 polymorphism in the human 5 alpha-reductase gene in primary breast cancer.	2001-03-23	11259089
Mechanism of pH-dependent photolysis of aliphatic amino acids and enantiomeric enrichment of racemic leucine by circularly polarized light.	2001-03-22	11263916
Catalytic asymmetric coupling of 2-naphthols by chiral tridentate oxovanadium (IV) complexes.	2001-03-22	11263903
Acetohydroxyacid synthase: a proposed structure for regulatory subunits supported by evidence from mutagenesis.	2001-03-16	11243831
Thrombomodulin Ala455Val polymorphism and risk of coronary heart disease.	2001-03-13	11245641
The Venus's-flytrap and cysteine-rich domains of the human Ca2+ receptor are not linked by disulfide bonds.	2001-03-09	11238442
Direct comparison of experimental and calculated folding free energies for hydrophobic deletion mutants of chymotrypsin inhibitor 2: free energy perturbation calculations using transition and denatured states from molecular dynamics simulations of unfolding.	2001-03-06	11258883
NMDA-responsible, APV-insensitive receptor in cultured human astrocytes.	2001-03-02	11270622
[Neurologic toxicity caused by zelitrex (valaciclovir) in 3 patients with renal failure. Is overdose associated with improvement of product bioavailability improvement?].	2001-03	11270274
Can angiotensin II receptor blockers be used in patients who have developed a cough or angioedema as a result of taking an ACE inhibitor?	2001-03	11263845
Novel molecular defects in the androgen receptor gene of Mexican patients with androgen insensitivity.	2001-03	11260228
The protection of rat liver autophagic proteolysis from the age-related decline co-varies with the duration of anti-ageing food restriction.	2001-03	11250121
Effect of valsartan on angiotensin II-induced plasminogen activator inhibitor-1 biosynthesis in arterial smooth muscle cells.	2001-03	11244025
Early alteration in glomerular reserve in humans at genetic risk of essential hypertension: mechanisms and consequences.	2001-03	11244015
Creutzfeldt-Jakob disease segregating in a three generation Danish family.	2001-03	11240560
A single amino acid change within antigenic domain II of the spike protein of bovine coronavirus confers resistance to virus neutralization.	2001-03	11238212
Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection.	2001-03	11231955
Purification, characterization and cloning of isovaleryl-CoA dehydrogenase from higher plant mitochondria.	2001-03	11231285
Isolation and characterisation of genomic and cDNA clones coding for a serine-, alanine-, and proline-rich protein of Trypanosoma cruzi.	2001-03	11226452
The analgesic interaction between intrathecal clonidine and glutamate receptor antagonists on thermal and formalin-induced pain in rats.	2001-03	11226109
Ligand migration in human myoglobin: steric effects of isoleucine 107(G8) on O(2) and CO binding.	2001-03	11222311
Acute effects of peritoneal dialysis with dialysates containing dextrose or dextrose and amino acids on muscle protein turnover in patients with chronic renal failure.	2001-03	11181804
Selected Contribution: IGF-I antibody prevents increases in protein synthesis in epitrochlearis muscles from refed, diabetic rats.	2001-03	11181633
Influence of permeating ions on Kv1.5 channel block by nifedipine.	2001-03	11179060
Fluorescence quenching properties and chemiluminescence responses of alpha-ketothiols derivatized with o-phthalaldehyde and primary amino compounds.	2001-02-17	11180654
Reduction of nonpolar amino acids to amino alcohols to enhance volatility for high-precision isotopic analysis.	2001-02-15	11248895
Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity.	2001-02-01	11221839
A molecular variant of the APC gene at codon 1822: its association with diet, lifestyle, and risk of colon cancer.	2001-02-01	11221825
Effect of polymorphisms on ligand binding by mouse major urinary proteins.	2001-02	11266626
[Cardioprotective mechanism of ischemic preconditioning is impaired by postinfarct ventricular remodeling through angiotensin II type 1 receptor activation].	2001-02	11255694
Conformational preferences of heterochiral peptides. Crystal structures of heterochiral peptides Boc-(D) Val-(D) Ala-Leu-Ala-OMe and Boc-Val-Ala-Leu-(D) Ala-OMe--enhanced stability of beta-sheet through C-H...O hydrogen bonds.	2001-02	11245253
Evaluation of valine requirement of the commercial layer using a corn-soybean meal basal diet.	2001-02	11233011
Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury.	2001-02	11230374
Endothelial dysfunction and salt-sensitive hypertension in spontaneously diabetic Goto-Kakizaki rats.	2001-02	11230314
Endothelial dysfunction and xanthine oxidoreductase activity in rats with human renin and angiotensinogen genes.	2001-02	11230310
Comparison of in vitro systems of protein digestion using either mammal or fish proteolytic enzymes.	2001-02	11223397
Renin-angiotensin system contribution to cardiac hypertrophy in experimental hyperthyroidism: an echocardiographic study.	2001-02	11209999
Novel fungal metabolites as cell wall active antifungals: fermentation, isolation, physico-chemical properties, structure and biological activity.	2001-01	11269717
Construction and physiological studies on a stable bioengineered strain of shengjimycin.	2001-01	11269716
Valine 77 of heterocystous ferredoxin FdxH2 in Anabaena variabilis strain ATCC 29413 is critical for its oxygen sensitivity.	2001-01	11269658
[Valaciclovir in the treatment of initial infection by genital herpes virus: comparative study].	2001-01	11256241
A silent mutation induces exon skipping in the phenylalanine hydroxylase gene in phenylketonuria.	2001-01	11214902
Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study.	2001-01	11206674
Reduction of wobble-position GC bases in Corynebacteria genes and enhancement of PCR and heterologous expression.	2001-01	11200224
Aseptic meningitis related to valacyclovir.	2001-01	11197578
An algorithm for mapping positively selected members of quasispecies-type viruses.	2001	11265061
Molecular cloning, expression, and regulation of hippocampal amyloid precursor protein of senescence accelerated mouse (SAMP8).	2001	11235921

Patents

Sample Use Guides

In Vivo Use Guide

Valine is administered with food or as a dietary supplement.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:34:49 GMT 2025` Edited by `admin` on `Mon Mar 31 17:34:49 GMT 2025`
Record UNII	HG18B9YRS7
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

L-VALINE

Preferred Name

English

VALINE

Official Name

English

L-VALINE [JAN]

Common Name

English

valine [INN]

Common Name

English

L-VALINE [FCC]

Common Name

English

VALINE [HSDB]

Common Name

English

VALINE [USP MONOGRAPH]

Common Name

English

VALINE [MART.]

Common Name

English

LYSINE ACETATE IMPURITY D [EP IMPURITY]

Common Name

English

VALINE [VANDF]

Common Name

English

VAL

Common Name

English

NSC-76038

Code

English

VALINE [MI]

Common Name

English

VALINE [EP MONOGRAPH]

Common Name

English

L-VALINE [USP-RS]

Common Name

English

(S)-2-AMINO-3-METHYLBUTANOIC ACID

Systematic Name

English

VALINE [USAN]

Common Name

English

VALINE [II]

Common Name

English

Valine [WHO-DD]

Common Name

English

Classification Tree Code System Code

LOINC

3119-5